Abstract
Obese hyperinsulinemic women with polycystic ovary syndrome (PCOS) present a markedly increased risk of developing glycaemic alterations during pregnancy, commonly recognized as a “diabetogenic” condition. This risk seems to be safely reduced by the administration of metformin during gestation. We analyzed the metabolic changes in two hyperinsulinemic PCOS women, who became pregnant after 8 weeks of metformin therapy and continued taking the drug till delivery. An oral glucose tolerance test and an euglycemic hyperinsulinemic clamp were performed at baseline and, during metformin therapy, in pre-conceptional state and at each trimester of gestation. A pronounced decrease in peripheral insulin sensitivity occurred as the pregnancies proceeded (at the third trimester 51.7% and 41.1% of pregestational values in patient 1 and 2 respectively), along with an increase in stimulated insulin secretion (at the third trimester 120% and 50.6% of pregestational values in patient 1 and 2 respectively). Despite these findings, none of the studied subjects developed gestational diabetes or impaired glucose tolerance. This confirms that metformin may exert a protective role against such disturbances in hyperinsulinemic PCOS patients, probably by avoiding the gestational physiologic changes leading to a loss of the metabolic balance achieved by these subjects out of pregnancy.
Similar content being viewed by others
References
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774–800.
Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002, 77: 209–15.
Lanzone A, Caruso A, Di Simone N, et al. Polycystic ovary syndrome. A risk factor for gestational diabetes? J Reprod Med 1995, 40: 312–6.
Lanzone A, Fulghesu AM, Cucinelli F, et al. Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Hum Reprod 1996, 11: 2382–6.
Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440–7.
Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001, 76: 326–31.
Adams J, Polson DW, Abdulwahid N. Multifollicular ovaries: clinical and endocrine features and response to gonadotropin releasing hormone. Lancet 1985, 2: 1375–8.
New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983, 57: 320–6.
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28: 1039–57.
Fulghesu AM, Cucinelli F, Pavone V, et al. Changes in luteinizing hormone and insulin secretion in polycystic ovary syndrome. Hum Reprod 1999, 14: 611–7.
Fulghesu AM, Apa R, Belosi C, et al. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment. Horm Res 2001, 55: 224–8.
O’Sullivan JM, Mahan M. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964, 13: 278–82.
Melczer Z, Bànhidy F, Csomor S, et al. Role of tumour necrosis factor-a in insulin resistance during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 105:7–10.
Ciampelli M, Lanzone A, Caruso A. Insulin in obstetrics: a main parameter in the management of pregnancy. Hum Reprod Update 1998, 4: 904–14.
Sepe JS, Connel FA, Geiss LS, Teutsch MS. Incidence, maternal characteristics, and perinatal outcome. Diabetes 1985, 34: 13–6.
Catalano PM. Carbohydrate metabolism and gestational diabetes. Clin Obstet Gynecol 1994, 37: 25–38.
Paradisi G, Fulghesu AM, Ferrazzani S, et al. Endocrinometabolic features in women with polycystic ovary sindrome during pregnancy. Hum Reprod 1998, 13: 542–6.
Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002, 77: 520–5.
Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002, 17: 2858–64.
Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 524–9.
Elliot BD, Langer O, Schuessling F. Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin. Am J Obstet Gynecol 1997, 176: 527–30
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guido, M., Romualdi, D., Belosi, C. et al. Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: A case report. J Endocrinol Invest 27, 70–75 (2004). https://doi.org/10.1007/BF03350915
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350915